Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide vs placebo on inflammation in Alzheimer’s disease
2023-506825-13-00Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) comparing Semaglutide arm with Placebo arm (2 arms). Primary endpoints: Change in gene expression in CSF cells and Change in gene expression in blood cells. Started Nov 2023; status: completed.
02
Drugs
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on 2023-506825-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506825-13-00.